V. Kansra

发表

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy‐Induced Nausea and Vomiting

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2019, Clinical pharmacology in drug development.

Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2018, Journal of clinical pharmacology.

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2018, Supportive Care in Cancer.

Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables

V. Kansra, J. Freeman, Xiaodong Wang, 2015, Journal of clinical pharmacology.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Cancer Chemotherapy and Pharmacology.

Diminished natriuretic response to dopamine in old rats is due to an impaired D1-like receptor-signaling pathway.

V. Kansra, M. Lokhandwala, T. Hussain, 2000, Kidney international.

Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates

V. Kansra, J. Freeman, Xiaodong Wang, 2015, Journal of clinical pharmacology.

Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2018, Clinical pharmacology in drug development.

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.

M. Zauderer, R. Cameron, D. Planchard, 2022, The Lancet. Oncology.

Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open‐Label Pivotal Study

J. Christensen, Zhi-yi Zhang, L. Hughes, 2017, Journal of clinical pharmacology.

Aging, high salt intake, and renal dopaminergic activity in Fischer 344 rats.

V. Kansra, M. Lokhandwala, P. Soares-da-Silva, 1999, Hypertension.

Small molecule antagonists of the CC chemokine receptor 4 (CCR4).

B. Jaffee, T. Ocain, J. Gonzalo, 2007, Bioorganic & medicinal chemistry letters.

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

K. Reddy, Jeffrey Anderson, I. Lowy, 2013, PloS one.

Phosphatidylinositol 3-Kinase-dependent Extracellular Calcium Influx Is Essential for CX3CR1-mediated Activation of the Mitogen-activated Protein Kinase Cascade*

R. Polakiewicz, J. Gutiérrez-Ramos, V. Kansra, 2001, The Journal of Biological Chemistry.

Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2018, Investigational new drugs.

Hyperphosphorylation of Na-pump contributes to defective renal dopamine response in old rats.

V. Kansra, M. Lokhandwala, T. Hussain, 2001, Journal of the American Society of Nephrology : JASN.

Renal dopamine receptor signaling mechanisms in spontaneously hypertensive and Fischer 344 old rats.

V. Kansra, M. Lokhandwala, T. Hussain, 1999, Clinical and experimental hypertension.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a pharmacokinetic study.

Zhi-yi Zhang, V. Kansra, C. Granvil, 2009, Journal of pharmaceutical and biomedical analysis.

Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.

G. Weiss, J. Infante, R. Martell, 2014 .

Alterations in dopamine DA1 receptor and G proteins in renal proximal tubules of old rats.

V. Kansra, M. Lokhandwala, T. Hussain, 1997, The American journal of physiology.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2017, Investigational New Drugs.

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

An Open‐Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2019, Clinical pharmacology in drug development.

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.

C. Gridelli, L. Urban, V. Kansra, 2015, The Lancet. Oncology.

Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2018, Journal of clinical pharmacology.

The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer

H. Burris, K. Moore, Zhi-yi Zhang, 2018, Cancer Chemotherapy and Pharmacology.

Dopamine causes stimulation of protein kinase C in rat renal proximal tubules by activating dopamine D1 receptors.

V. Kansra, M. Lokhandwala, C. Chen, 1995, European journal of pharmacology.

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant

M. Aapro, X. Wang, V. Kansra, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dopamine fails to stimulate protein kinase C activity in renal proximal tubules of spontaneously hypertensive rats.

V. Kansra, M. Lokhandwala, Changjian Chen, 1995, Clinical and experimental hypertension.

Dopaminergic modulation of Na,K-ATPase activity in the proximal tubules of normotensive and hypertensive rats.

V. Kansra, M. Lokhandwala, C. Chen, 1995, Hypertension research : official journal of the Japanese Society of Hypertension.

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut.

H. Ploegh, W. Garrett, J. Glickman, 2023, Cell host & microbe.

A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.

R. Kurzrock, E. Galanis, R. Martell, 2014 .

A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic

Zhi-yi Zhang, V. Kansra, Xiaodong Wang, 2018, Clinical pharmacology in drug development.

Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P‐glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers

J. Christensen, Zhi-yi Zhang, L. Hughes, 2018, Journal of clinical pharmacology.

Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers

X. Wang, J. Wang, V. Kansra, 2017, Clinical pharmacology and therapeutics.

Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist.

R. Martell, J. Christensen, V. Kansra, 2014 .

Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate.

Zhi-yi Zhang, V. Kansra, Zhi-Yi Zhang, 2009, Journal of pharmaceutical and biomedical analysis.

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

A. Borisy, Margaret S. Lee, R. Rickles, 2008, Molecular Cancer Therapeutics.

933PDThe exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial

A. Tinker, J. Berek, U. Matulonis, 2017 .

Characterization of Absorption, Metabolism, and Elimination of Niraparib, an Investigational Poly (ADP-Ribose) Polymerase Inhibitor, in Cancer Patients

J. Schellens, H. Rosing, J. Beijnen, 2017 .

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Margaret S. Lee, R. Rickles, Laura T. Pierce, 2012, Molecular Cancer Therapeutics.